AUTHORS
Sudipto Mukherjee, MD, PhD, MPH, Jill Carlton, PhD2, Annmarie Bosco, MBBS, FRACP, FRCPA3, Antonio Adolfo Guerra Soares Brandão, MD4, Corey Casper, MD, PhD5, Luke Chen, MD6, Ignatius Chua, MD7, Kelley C Dacus, PharmD8, David Fajgenbaum, MD, MBA, MSc9, Se Maria Frances, PhD10, Satyen Gohil, MD, PhD, MRCP, FRCPath11, Anju Keetharuth, PhD12, Yildiz Kelahmetoglu, PhD13, Kelly Makarounas-Kirchmann, MEC14, Eric Oksenhendler, MD15, H. Miles Prince, MD16, Karthik Ramasamy, MD PhD17, Yeow Tee Goh, MD, MBBS18, Francis Shupo, MSc19, Gordan Srkalovic, MD20, Craig Wallington-Gates, MD21, Frits van Rhee, MD, PhD22, Lu Zhang, MD23, Pier Luigi Zinzani, MD, PhD24, Phil A Powell, PhD25
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 The University of Sheffield, Sheffiled, United Kingdom
3 Prince of Wales Hospital, Sydney, Australia
4 A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
5 Banner Health, Phoenix, Arizona, United States
6 Dalhousie University, Halifax, Canada
7 Christchurch Hospital, Christchurch, New Zealand
8 Recordati Rare Diseases, Lebanon, New Jersey, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 The University of Sheffield, Sheffiled, United Kingdom
11 University College London Hospitals NHS Foundation Trust, London, United Kingdom
12 The University of Sheffield, Sheffield, United Kingdom
13 Recordati Rare Diseases, Hemel Hempstead, United Kingdom
14 KMC Health Care, Melbourne, Australia
15 Hopital Saint Louis, Paris, France, Paris, France
16 Peter MacCallum Cancer Inst., Melbourne, Australia
17 Oxford, Oxford, United Kingdom
18 Singapore General Hospital, Singapore, Singapore
19 Recordati Rare Diseases, Hemel Hempstead, United Kingdom
20 University of Michigan Health-Sparrow Herbert-Herman Cancer Center, Michigan, United States
21 Sunshine Coast University Hospital, Sunshine Coast, Australia
22 University of Arkansas for Medical Sciences, Arkansas, United States
23 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking, China
24 University of Bologna, Bologna, Italy
25 Clarivate, London, United Kingdom
ABSTRACT
Introduction:
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder, with an estimated prevalence of approximately 3 cases per million, characterized by generalized lymphadenopathy and a chronic hyperinflammatory state. As no curative therapies currently exist, management is primarily directed towards controlling disease manifestations and reducing symptom burden, which remains substantial and is associated with marked impairment in quality of life (QoL). However, the absence of a disease-specific patient-reported outcome measure (PROM) limits the systematic assessment of symptom burden and treatment response, representing a significant unmet need in this population.
Aim:
To develop and validate the iMCD Symptom Burden Scale (ISBUS: NCT05995834), a novel PROM for assessing and quantifying symptom burden in people with iMCD.
Methods:
PROM development comprised four phases, guided throughout by a multidisciplinary advisory group of patients, clinicians, researchers, and industry partners: (1) item generation, (2) cognitive interviewing, (3) psychometric evaluation and (4) assessment of meaningful change. Ethics approval and informed consent were obtained. Phase 1 generated a draft PROM from the literature, symptom surveys, international experts (n=12) and patient advisors (n=3). Phase 2 cognitive interviews (n=10) refined a 42-item questionnaire. In Phase 3, participants from six countries (n=52) completed ISBUS alongside established symptom and QoL measures, with psychometric analyses informing refinement of the final instrument. Phase 4 evaluated meaningful change through repeat surveys and qualitative interviews. Statistical analyses included factor analysis, correlations, Cronbach's α and intraclass correlation coefficients (ICC).
Results:
In Phase 1, 42 symptoms were drafted, with two response scales assessing frequency and severity (perceived impact on life). Based on patient and clinician advice, an initial recall period of the past week and 4-point response scales were adopted. In Phase 2, all 42 candidate symptoms were reviewed, 30 items were retained following participant feedback. Respondents reported that the questionnaire captured the breadth of their symptoms and was generally easy to understand. Symptoms considered less relevant to iMCD or too similar and therefore redundant were removed. Minor wording changes improved clarity, such as replacing “difficulty breathing” with “shortness of breath”.
In Phase 3, 52 participants completed the psychometric survey (US n=25, Canada n=11, UK n=9, Australia n=5, New Zealand=1, Brazil n=1). Integrating psychometric findings with patient and clinical expert input resulted in a concise 12-item scale. The final instrument demonstrated good structural validity, supporting the proposed conceptual structure (χ²(54) = 67.70, p = .10; RMSR = 0.08; TLI = 0.93), high internal consistency (Cronbach's α = 0.91), and good convergent validity, as evidenced by strong correlations with validated measures of symptoms (rₛ = 0.87) and QoL (rₛ = −0.77). In Phase 4, 32 participants completed a repeat survey, and 10 participants were interviewed. Estimates of minimal meaningful change varied across participants, ranging from 0.5 to 3 points (mean=1.55; median=1.65). Eighteen participants reported no change in their health (i.e., “stayed the same”) and the ICC estimate of test-retest reliability in this subgroup was excellent (ICC (2,1) = 0.86, 95% CI 0.67–0.95, n = 18).
Conclusions:
ISBUS is the first disease-specific PROM developed to assess symptom burden in iMCD patients. Built through international collaboration among patients, clinicians, researchers and industry partners, it demonstrates strong content validity, comprehensibility and relevance to the lived experience of iMCD, regardless of treatment status. The final instrument demonstrated sound structural validity, strong internal consistency and convergent validity, supporting its measurement performance against established generic and iMCD-specific symptom and QoL measures. Phase 4 findings further offer insight into meaningful change in iMCD symptom burden scores, supporting interpretation of results over time. Collectively, these findings provide robust evidence supporting the validity and measurement performance of ISBUS for assessing symptom burden in patients with iMCD, with potential utility in future clinical research.
DISCLOSURES
Sudipto Mukherjee, MD, PhD, MPH: Sobi - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); CCM Biosciences - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); McGraw Hill - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony)